Table of Contents List of Tables List of Figures Introduction Global Markets Direct Report Coverage Mitogen Activated Protein Kinase 8 (c Jun N Terminal Kinase 1 or JNK 46 or Stress Activated Protein Kinase JNK1 or Stress Activated Protein Kinase 1c or MAPK8 or EC 2.7.11.24) - Overview Mitogen Activated Protein Kinase 8 (c Jun N Terminal Kinase 1 or JNK 46 or Stress Activated Protein Kinase JNK1 or Stress Activated Protein Kinase 1c or MAPK8 or EC 2.7.11.24) - Therapeutics Development Products under Development by Stage of Development Products under Development by Therapy Area Products under Development by Indication Products under Development by Companies Products under Development by Universities/Institutes Mitogen Activated Protein Kinase 8 (c Jun N Terminal Kinase 1 or JNK 46 or Stress Activated Protein Kinase JNK1 or Stress Activated Protein Kinase 1c or MAPK8 or EC 2.7.11.24) - Therapeutics Assessment Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Mitogen Activated Protein Kinase 8 (c Jun N Terminal Kinase 1 or JNK 46 or Stress Activated Protein Kinase JNK1 or Stress Activated Protein Kinase 1c or MAPK8 or EC 2.7.11.24) - Companies Involved in Therapeutics Development Celgene Corp OPKO Health Inc Xigen SA Mitogen Activated Protein Kinase 8 (c Jun N Terminal Kinase 1 or JNK 46 or Stress Activated Protein Kinase JNK1 or Stress Activated Protein Kinase 1c or MAPK8 or EC 2.7.11.24) - Drug Profiles brimapitide - Drug Profile Product Description Mechanism Of Action R&D Progress CC-90001 - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Activate JNK-1, JNK-2 and p38 MAP Kinase for Breast Cancer - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit JNK1, JNK2 and JNK3 for Parkinson’s Disease - Drug Profile Product Description Mechanism Of Action R&D Progress SR-3306 - Drug Profile Product Description Mechanism Of Action R&D Progress Mitogen Activated Protein Kinase 8 (c Jun N Terminal Kinase 1 or JNK 46 or Stress Activated Protein Kinase JNK1 or Stress Activated Protein Kinase 1c or MAPK8 or EC 2.7.11.24) - Dormant Products Mitogen Activated Protein Kinase 8 (c Jun N Terminal Kinase 1 or JNK 46 or Stress Activated Protein Kinase JNK1 or Stress Activated Protein Kinase 1c or MAPK8 or EC 2.7.11.24) - Product Development Milestones Featured News & Press Releases Mar 11, 2019: Auris Medical announces publication of AM-111 phase 3 results in peer-reviewed scientific journal Aug 30, 2018: Auris Medical Receives FDA Guidance at Type C Meeting for AM-111 in the Treatment of Sudden Sensorineural Hearing Loss May 07, 2018: Auris Medical Receives Positive Scientific Advice from EMA on Development Plan and Regulatory Pathway for AM-111 May 04, 2018: Auris Medical Announces Publication Related to AM-111 in Peer-Reviewed Scientific Journal Jan 04, 2018: Auris Medical Provides Update on AM-111 Development Program Dec 28, 2017: Auris Medical to Provide Update on Its AM-111 Hearing Loss Program Nov 28, 2017: Auris Medical Reports Top-Line Results from Phase 3 Trial of AM-111 in Sudden Deafness Jul 05, 2017: Auris Medical Completes Enrollment of Phase 3 HEALOS Trial of AM-111 for the Treatment of Sudden Deafness Feb 24, 2017: Auris Medical Receives FDA Fast Track Designation for AM-111 in Acute Sensorineural Hearing Loss Jan 05, 2017: Xigens Brimapitide, an Innovative JNK Inhibitor, Delivers Positive Phase II Results in Inflammatory Eye Disease Sep 09, 2016: Auris Medical Achieves Midpoint for Enrollment in Phase 3 Trial of AM-111 in Sudden Deafness Jun 17, 2016: Auris Medical Initiates ASSENT Phase 3 Trial of AM-111 for Treatment of Sudden Deafness Nov 13, 2015: Auris Medical Announces Enrollment of First Patient in HEALOS Study of AM-111 in Treatment of Idiopathic Sudden Sensorineural Hearing Loss Jun 25, 2015: Auris Medical and Cochlear to Collaborate on Clinical Trial with AM-111 for Otoprotection during Cochlear Implant Surgery May 04, 2015: Auris Medical Holding Provides Update on Clinical Development Plan for AM-111 Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer

List of Tables Number of Products under Development by Stage of Development, H1 2019 Number of Products under Development by Therapy Areas, H1 2019 Number of Products under Development by Indication, H1 2019 Number of Products under Development by Companies, H1 2019 Products under Development by Companies, H1 2019 Number of Products under Investigation by Universities/Institutes, H1 2019 Products under Investigation by Universities/Institutes, H1 2019 Number of Products by Stage and Mechanism of Actions, H1 2019 Number of Products by Stage and Route of Administration, H1 2019 Number of Products by Stage and Molecule Type, H1 2019 Pipeline by Celgene Corp, H1 2019 Pipeline by OPKO Health Inc, H1 2019 Pipeline by Xigen SA, H1 2019 Dormant Projects, H1 2019List of Figures Number of Products under Development by Stage of Development, H1 2019 Number of Products under Development by Therapy Areas, H1 2019 Number of Products under Development by Top 10 Indications, H1 2019 Number of Products by Mechanism of Actions, H1 2019 Number of Products by Stage and Mechanism of Actions, H1 2019 Number of Products by Routes of Administration, H1 2019 Number of Products by Stage and Routes of Administration, H1 2019 Number of Products by Molecule Types, H1 2019 Number of Products by Stage and Molecule Types, H1 2019

Celgene Corp OPKO Health Inc Xigen SA